Akèy › Tit travay › Scientist II
Scientist II: Salè H-1B
569 aplikasyon kondisyon travay te itilize tit travay Scientist II. Salè baz medyàn ofri $98,193; mwatye mitan $80,000–$125,000.
Demann (LCA)569
Salè medyan ofri$98,193
Mwatye salè yo$80,000–$125,000
10yèm–90yèm pousantaj$61,919–$140,000
Avoka imigrasyon, rekritè oswa anplwayè? Mete sèvis ou an tèt paj sa a — $99 pou 30 jou →
Anplwayè yo
| Anplwayè | LCA | Salè medyan |
|---|
| University of Wisconsin System | 67 | $78,551 |
| Allen Institute | 27 | $98,314 |
| Dana-Farber Cancer Institute | 22 | $101,672 |
| University of Kentucky | 21 | $66,685 |
| Eurofins BioPharma Product Testing Columbia, LLC. | 16 | $50,000 |
| Triad National Security, LLC | 11 | $144,000 |
| The University of Alabama at Birmingham | 11 | $79,806 |
| Eurofins Professional Scientific Services Mid-Atlantic, LLC. | 11 | $51,356 |
| California Institute of Technology/Jet Propulsion Laboratory | 9 | $124,072 |
| Riconpharma, LLC | 9 | $85,000 |
| Tessera Therapeutics, Inc. | 9 | $130,000 |
| Eurofins Lancaster Laboratories LLC | 8 | $51,127 |
| WuXi Biologics USA, LLC | 7 | $85,000 |
| Metagenomi, Inc. | 7 | $130,000 |
| Abzena (Bristol) LLC | 6 | $106,235 |
| 10x Genomics, Inc. | 6 | $140,000 |
| Tufts University | 6 | $89,600 |
| AIR Worldwide Corporation | 6 | $113,530 |
| Frontage Laboratories, Inc. | 6 | $78,875 |
| Leidos Biomedical Research, Inc. | 5 | $114,629 |
| The Henry M. Jackson Foundation | 5 | $112,500 |
| Novozymes North America, Inc. | 4 | $103,251 |
| Entrada Therapeutics, Inc. | 4 | $136,380 |
| BioAgilytix Labs, LLC | 4 | $118,762 |
| Inventprise Inc | 4 | $115,000 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $86,292 |
| Nutrition & Biosciences, USA 4, Inc. | 4 | $95,243 |
| Danisco US Inc. | 4 | $109,450 |
| CZ Biohub SF, LLC | 4 | $139,776 |
| Eurofins Professional Scientific Services New England, LLC. | 4 | $57,824 |
| EntroGen Inc. | 3 | $100,000 |
| Eurofins DiscoveRX Corporation | 3 | $75,005 |
| Mammoth Biosciences Inc. | 3 | $140,213 |
| Abbvie Biotherapeutics Inc. | 3 | $125,000 |
| Kumquat Biosciences, Inc. | 3 | $125,000 |
| Arcellx, Inc. | 3 | $145,000 |
| Pace Analytical Life Sciences, LLC | 3 | $90,640 |
| Zenith LifeScience LLC | 3 | $93,600 |
| Sanford Burnham Prebys Medical Discovery Institute | 3 | $110,000 |
| Hexagon Bio, Inc. | 3 | $140,000 |
| Granules Pharmaceuticals Inc. | 3 | $83,928 |
| Eurofins Professional Scientific Services Midwest, LLC. | 3 | $45,823 |
| Eurofins Advantar Laboratories, Inc | 2 | $65,499 |
| Vor Biopharma Inc. | 2 | $130,000 |
| Ann Arbor Algorithms Inc | 2 | $100,000 |
| Senti Biosciences, Inc. | 2 | $129,355 |
| Dyno Therapeutics, Inc. | 2 | $136,596 |
| Pharmaron (Boston) Lab Services, LLC | 2 | $71,635 |
| Stowers Institute for Medical Research | 2 | $85,638 |
| Cerus Corporation | 2 | $129,450 |
| Voyager Therapeutics, Inc. | 2 | $129,608 |
| Zymergen Inc. | 2 | $144,000 |
| Flagship Labs 85, Inc. | 2 | $120,000 |
| Vitae Enim Vitae Scientific Inc. | 2 | $75,920 |
| RxD Nova Pharmaceutical, Inc | 2 | $80,000 |
| McNeal Professional Services, Inc. | 2 | $75,244 |
| ReCode Therapeutics, Inc. | 2 | $135,000 |
| Seer, Inc. | 2 | $134,058 |
| Tacere Therapeutics, Inc. | 2 | $142,186 |
| Oxford Biomedica Solutions LLC | 2 | $130,913 |
Pa nivo salè
| Nivo revni | Salè medyan |
|---|
| Nivo I (antre) | $85,000 |
| Nivo II (kalifye) | $94,650 |
| Nivo III (eksperyans) | $125,290 |
| Nivo IV (plen kompetans) | $131,019 |
Depatman Travay la etabli kat nivo salè prevanlan pou chak okipasyon ak zòn, soti nan Nivo I (antre) rive nan Nivo IV (plen kompetans). Anplwayè a chwazi nivo ki koresponn ak kondisyon travay la.
Pa ane fiskal
| Ane fiskal | LCA | Salè medyan |
|---|
| FY2023 | 98 | $93,700 |
| FY2024 | 122 | $100,625 |
| FY2025 | 162 | $103,525 |
| FY2026 | 155 | $94,328 |
Vil yo
- Madison, WI67
- Boston, MA46
- Seattle, WA27
- Cambridge, MA21
- Lexington, KY21
- San Diego, CA18
- South San Francisco, CA16
- Columbia, MO16
- Birmingham, AL12
- Emeryville, CA12
- Los Alamos, NM11
- Somerville, MA10
- West Point, PA10
- Pasadena, CA9
- Denville, NJ9
- Cranbury, NJ9
- Lancaster, PA8
- Watertown, MA7
- Pleasanton, CA7
- Exton, PA6
- Bristol, PA6
- New York, NY6
- Silver Spring, MD6
- Redwood City, CA6
- Durham, NC6
- San Francisco, CA6
- Dallas, TX5
- Menlo Park, CA5
- Houston, TX5
- Brisbane, CA5
Salè yo se fen ki pi ba nan salè yo ofri sou chak aplikasyon, konvèti nan yon montan anyèl; estatistik yo itilize sèlman aplikasyon tan plen sètifye. Yon LCA pa yon apwobasyon visa epi yon sèl LCA ka kouvri plizyè pozisyon. Sous: Depatman Travay Etazini, Done Divulgasyon LCA OFLC, ane fiskal 2023–2026 (dènye desizyon Jun 30, 2026).